MEDEXUS PHARMACEUTICALS INC (MDP.CA) Stock Fundamental Analysis
Canada - TSX:MDP - CA58410Q2036 - Common Stock
2.71 CAD
-0.14 (-4.91%)
We assign a fundamental rating of 4 out of 10 to MDP. MDP was compared to 32 industry peers in the Pharmaceuticals industry. Both the profitability and the financial health of MDP get a neutral evaluation. Nothing too spectacular is happening here. MDP has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year MDP was profitable.
In the past year MDP had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: MDP reported negative net income in multiple years.
The reported operating cash flow has been mixed in the past 5 years: MDP reported negative operating cash flow in multiple years.
1.2 Ratios
With a decent Return On Assets value of 0.52%, MDP is doing good in the industry, outperforming 78.13% of the companies in the same industry.
With a decent Return On Equity value of 1.52%, MDP is doing good in the industry, outperforming 78.13% of the companies in the same industry.
MDP has a better Return On Invested Capital (8.11%) than 90.63% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MDP is in line with the industry average of 7.94%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.52% | ||
| ROE | 1.52% | ||
| ROIC | 8.11% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
1.3 Margins
MDP has a better Profit Margin (0.76%) than 71.88% of its industry peers.
MDP has a better Operating Margin (7.99%) than 78.13% of its industry peers.
The Gross Margin of MDP (52.55%) is better than 81.25% of its industry peers.
MDP's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.99% | ||
| PM (TTM) | 0.76% | ||
| GM | 52.55% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so MDP is still creating some value.
MDP has more shares outstanding than it did 1 year ago.
The number of shares outstanding for MDP has been increased compared to 5 years ago.
Compared to 1 year ago, MDP has an improved debt to assets ratio.
2.2 Solvency
MDP has an Altman-Z score of 0.57. This is a bad value and indicates that MDP is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MDP (0.57) is better than 65.63% of its industry peers.
The Debt to FCF ratio of MDP is 1.29, which is an excellent value as it means it would take MDP, only 1.29 years of fcf income to pay off all of its debts.
MDP has a better Debt to FCF ratio (1.29) than 93.75% of its industry peers.
MDP has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, MDP belongs to the top of the industry, outperforming 90.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.29 | ||
| Altman-Z | 0.57 |
ROIC/WACC0.93
WACC8.75%
2.3 Liquidity
A Current Ratio of 0.81 indicates that MDP may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.81, MDP is doing worse than 87.50% of the companies in the same industry.
A Quick Ratio of 0.37 indicates that MDP may have some problems paying its short term obligations.
MDP's Quick ratio of 0.37 is on the low side compared to the rest of the industry. MDP is outperformed by 87.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.37 |
3. Growth
3.1 Past
The earnings per share for MDP have decreased strongly by -50.00% in the last year.
MDP shows a decrease in Revenue. In the last year, the revenue decreased by -2.87%.
MDP shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.82% yearly.
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
Revenue 1Y (TTM)-2.87%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-9.78%
3.2 Future
MDP is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 53.29% yearly.
MDP is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.19% yearly.
EPS Next Y-115.78%
EPS Next 2Y96.23%
EPS Next 3Y96.39%
EPS Next 5Y53.29%
Revenue Next Year-5.78%
Revenue Next 2Y4.88%
Revenue Next 3Y8.64%
Revenue Next 5Y10.19%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 90.33, the valuation of MDP can be described as expensive.
MDP's Price/Earnings ratio is a bit cheaper when compared to the industry. MDP is cheaper than 78.13% of the companies in the same industry.
MDP is valuated expensively when we compare the Price/Earnings ratio to 27.34, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 6.28, the valuation of MDP can be described as very cheap.
90.63% of the companies in the same industry are more expensive than MDP, based on the Price/Forward Earnings ratio.
MDP's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.86.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 90.33 | ||
| Fwd PE | 6.28 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of MDP indicates a rather cheap valuation: MDP is cheaper than 96.88% of the companies listed in the same industry.
90.63% of the companies in the same industry are more expensive than MDP, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.68 | ||
| EV/EBITDA | 4.51 |
4.3 Compensation for Growth
MDP's earnings are expected to grow with 96.39% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y96.23%
EPS Next 3Y96.39%
5. Dividend
5.1 Amount
No dividends for MDP!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
TSX:MDP (10/10/2025, 7:00:00 PM)
2.71
-0.14 (-4.91%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners3.1%
Inst Owner ChangeN/A
Ins Owners7.27%
Ins Owner ChangeN/A
Market Cap87.42M
Analysts82.22
Price Target6.3 (132.47%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)101.23%
Min EPS beat(2)58.46%
Max EPS beat(2)144%
EPS beat(4)3
Avg EPS beat(4)43.05%
Min EPS beat(4)-100%
Max EPS beat(4)144%
EPS beat(8)5
Avg EPS beat(8)4.43%
EPS beat(12)9
Avg EPS beat(12)92.45%
EPS beat(16)10
Avg EPS beat(16)67.52%
Revenue beat(2)0
Avg Revenue beat(2)-0.53%
Min Revenue beat(2)-0.63%
Max Revenue beat(2)-0.44%
Revenue beat(4)1
Avg Revenue beat(4)1.34%
Min Revenue beat(4)-0.63%
Max Revenue beat(4)6.82%
Revenue beat(8)2
Avg Revenue beat(8)-2.13%
Revenue beat(12)5
Avg Revenue beat(12)0.19%
Revenue beat(16)8
Avg Revenue beat(16)1.71%
PT rev (1m)0%
PT rev (3m)0.93%
EPS NQ rev (1m)0%
EPS NQ rev (3m)89.93%
EPS NY rev (1m)79.17%
EPS NY rev (3m)86.98%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.92%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.84%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 90.33 | ||
| Fwd PE | 6.28 | ||
| P/S | 0.59 | ||
| P/FCF | 3.68 | ||
| P/OCF | 3.16 | ||
| P/B | 1.18 | ||
| P/tB | N/A | ||
| EV/EBITDA | 4.51 |
EPS(TTM)0.03
EY1.11%
EPS(NY)0.43
Fwd EY15.92%
FCF(TTM)0.74
FCFY27.15%
OCF(TTM)0.86
OCFY31.66%
SpS4.59
BVpS2.3
TBVpS-1.16
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.52% | ||
| ROE | 1.52% | ||
| ROCE | 11.27% | ||
| ROIC | 8.11% | ||
| ROICexc | 9.27% | ||
| ROICexgc | N/A | ||
| OM | 7.99% | ||
| PM (TTM) | 0.76% | ||
| GM | 52.55% | ||
| FCFM | 16.03% |
ROA(3y)0.64%
ROA(5y)-3.83%
ROE(3y)3.01%
ROE(5y)-32.83%
ROIC(3y)9.89%
ROIC(5y)N/A
ROICexc(3y)12.45%
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)13.73%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.84%
GM growth 5Y-1.43%
F-Score5
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 1.29 | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 34.4% | ||
| Cap/Sales | 2.67% | ||
| Interest Coverage | 2.18 | ||
| Cash Conversion | 118.79% | ||
| Profit Quality | 2101.86% | ||
| Current Ratio | 0.81 | ||
| Quick Ratio | 0.37 | ||
| Altman-Z | 0.57 |
F-Score5
WACC8.75%
ROIC/WACC0.93
Cap/Depr(3y)16.17%
Cap/Depr(5y)70.8%
Cap/Sales(3y)1.03%
Cap/Sales(5y)5.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-50%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-75%
EPS Next Y-115.78%
EPS Next 2Y96.23%
EPS Next 3Y96.39%
EPS Next 5Y53.29%
Revenue 1Y (TTM)-2.87%
Revenue growth 3Y12.2%
Revenue growth 5Y7.82%
Sales Q2Q%-9.78%
Revenue Next Year-5.78%
Revenue Next 2Y4.88%
Revenue Next 3Y8.64%
Revenue Next 5Y10.19%
EBIT growth 1Y-31.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year45.65%
EBIT Next 3Y60.67%
EBIT Next 5Y50.41%
FCF growth 1Y164.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y191.19%
OCF growth 3YN/A
OCF growth 5YN/A